Pharmacotherapy remains the cornerstone of modern cardiology, contributing significantly to reduced morbidity and mortality in cardiovascular diseases (CVDs). This review explores contemporary pharmacologic interventions in key cardiologic conditions including hypertension, heart failure, coronary artery disease, and arrhythmias. A critical analysis of drug classes such as beta-blockers, ACE inhibitors, ARBs, anticoagulants, antiplatelets, statins, and novel agents like SGLT2 inhibitors is presented. The paper also discusses emerging therapeutic targets and challenges associated with drug adherence and polypharmacy. Future directions for personalized medicine, pharmacogenomics, and digital adherence tools are highlighted. This synthesis aims to inform practitioners and researchers of evolving trends and unresolved issues in cardiologic pharmacotherapy.

Cardiovascular diseases (CVDs) remain the leading cause of death globally, accounting for nearly 18 million deaths annually. Pharmacologic treatment plays a central role in both the acute and chronic management of cardiac conditions. Over the past decades, advances in pharmacotherapy have revolutionized the prognosis of diseases such as heart failure, myocardial infarction, and arrhythmias. Despite significant progress, optimal pharmacologic management continues to face several challenges,  including  patient  non-compliance,  drug interactions, and the rising prevalence of multi-morbidity. With the advent of new drug classes and improved understanding of diseasemechanisms, pharmacotherapy in cardiology is undergoing rapid evolution. This paper provides a structured review of current pharmacologic approaches in cardiology and outlines future perspectives in this domain.

This study was conducted as a narrative literature review. A comprehensive search was performed across PubMed, Scopus, Web of Science, and Cochrane Library databases using keywords such as “cardiology”, “cardiovascular drugs”, “pharmacotherapy in heart failure”,“beta-blockers in CVD”, and “SGLT2 inhibitors in cardiology”. Articles published in English between 2015 and 2024 were included. Inclusion criteria comprised randomized controlled trials (RCTs), systematic reviews, meta-analyses, and major clinical guidelines from organizations such as the European Society of Cardiology (ESC), AmericanHeart Association (AHA), and National Institute for Health and Care Excellence (NICE). Data were extracted and thematically organized under disease-specific categories.

1. Hypertension Management

First-line agents including thiazide diuretics, ACE inhibitors, calcium channel blockers, and beta-blockers are supported by strong evidence for blood pressure control. Fixed-dose combinations have improved adherence, while guidelines increasingly emphasize individualized therapy based on comorbidities and age.

2. Heart Failure Pharmacotherapy

Current standard therapy includes ACE inhibitors (or ARBs), beta-blockers, mineralocorticoid receptor antagonists, and more recently, angiotensin receptor-neprilysin inhibitors (ARNIs). The incorporation of SGLT2 inhibitors (dapagliflozin, empagliflozin) has shown significant mortality and morbidity benefits, irrespective of diabetes status.

3. Ischemic Heart Disease and Acute Coronary Syndrome

Antiplatelet therapy (aspirin, P2Y12 inhibitors) remains the foundation for secondary prevention. Statins are universally recommended, and PCSK9 inhibitors have demonstrated LDL-lowering efficacy in statin-intolerant or high-risk patients. Recent trials support shorter durations of dual antiplatelet therapy in selected low-bleeding-risk populations.

4. Atrial Fibrillation and Anticoagulation

Direct oral anticoagulants (DOACs) have largely replaced warfarin due to better safety profiles. Risk stratification using CHA₂DS₂-VASc and HAS-BLED scores guide therapy decisions. Emerging data support left atrial appendage occlusion in select patients contraindicated for long-term anticoagulation.

5. Emerging Therapies

Innovations include RNA-based therapies, anti-inflammatory agents (e.g., colchicine), and GLP-1 receptor agonists with cardioprotective potential. Pharmacogenomics is also influencing drug response prediction, particularly for clopidogrel and warfarin.

The pharmacological management of cardiovascular disease is in a state of continual refinement. While established therapies have proven benefits, their implementation is often hampered by issues such as nonadherence, cost, and side effects. Polypharmacy in elderly or comorbid patients adds complexity, making medication reconciliation and deprescribing vital components of care. SGLT2 inhibitors represent a paradigm shift, showing robust cardiovascular benefits across a spectrum of conditions. Likewise, the move from warfarin to DOACs simplifies management and improves safety in anticoagulation therapy. Yet, challenges persist. Ethnic and genetic variations affecting drug metabolism, the burden of lifestyle modification, and the digital divide in accessing adherence tools limit optimal outcomes. The integration of artificial intelligence, wearable monitoring devices, and personalized pharmacogenetic profiling holds promise for future improvements.

Pharmacotherapy in cardiology has progressed substantially, offering a robust arsenal for the management of CVDs. Continued research, patient-centered care models, and the adoption of emerging technologies will be essential in optimizing outcomes. A strategic shift towards personalized medicine, alongside system-level interventions to ensure access and adherence, will define the next phase of advancement in cardiovascular therapeutics.